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Sjögren's syndrome (SS) is a chronic autoimmune disease targeting salivary and lacrimal 
glands. C-X-C motif chemokine ligand 10 (CXCL10) expression is upregulated in lip salivary 
glands (LSGs) of primary SS (pSS) patients, and CXCL10 involved in SS pathogenesis via 
immune-cell accumulation. Moreover, interferon (IFN)- enhances CXCL10 production via 
the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. We 
investigated the effects of baricitinib, a selective JAK1/2 inhibitor, on both IFN- -induced 
CXCL10 production and immune-cell chemotaxis. We used immunohistochemical staining to 
determine the expression levels and localization of JAK1 and JAK2 in LSGs of SS patients 
(n=12) and healthy controls (n=3). We then evaluated effect of baricitinib in an immortalized 
normal human salivary gland ductal (NS-SV-DC) cell line. Immunohistochemical analysis of 
LSGs from pSS patients revealed strong JAK1 and JAK2 expression in ductal and acinar cells, 
respectively. Baricitinib significantly inhibited IFN- -induced CXCL10 expression as well as 
the protein levels in an immortalized human salivary gland ductal-cell clone in a 
dose-dependent manner. Additionally, western blot analysis showed that baricitinib 
suppressed the IFN- -induced phosphorylation of STAT1 and STAT3, with a stronger effect 
observed in case of STAT1. It also inhibited IFN- -mediated chemotaxis of Jurkat T cells. 
These results suggested that baricitinib suppressed IFN- -induced CXCL10 expression and 
attenuated immune-cell chemotaxis by inhibiting JAK/STAT signaling, suggesting its 
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Sjögren's syndrome (SS) is among the most common autoimmune diseases [1, 2] and is 
characterized by the destruction of acinar structure by marked lymphocytic infiltrates in the 
salivary and lacrimal glands, which results in sicca symptoms in affected patients [3–5]. SS 
pathogenesis is complicated and involves genetic contributions, frequency of the particular 
infection, and individual susceptibility to activating immune responses [6].  
Recent data suggest central roles for interferon (IFN) types I (IFN- and - and II 
(IFN- in SS pathogenesis based on the upregulation of their target genes in peripheral blood 
[7] and lip salivary glands (LSGs) [8, 9] from SS patients. In LSGs from SS patients, 
plasmacytoid dendritic cells are the main source of IFN- whereas CD4+ T cells and natural 
killer cells are the main IFN- producers [10]. Furthermore, the type I IFN signature is 
prevalent in the peripheral blood of SS patients, whereas the type II IFN signature 
predominates in LSGs [11].  
C-X-C motif chemokine ligand 10 (CXCL10) is a chemokine induced by IFN-  and 
produced by diverse cell types, including peripheral blood mononuclear cells, fibroblasts, and 
endothelial cells, during T helper 1 cell-mediated immune responses [12]. CXCL10 and its 
receptor, CXC receptor 3 (CXCR3) apparently contribute to the pathogenesis of many 
autoimmune diseases, including SS [13]. Gene-expression profiling of LSGs from healthy 
subjects and primary SS (pSS) patients demonstrated that CXCL10 is clearly upregulated in 




cells in the salivary glands of pSS patients [14, 15], and recent in vitro experiments showed 
that IFN- enhanced CXCL10 production via both the Janus kinase (JAK)/signal transducer 
and activator of transcription (STAT) and nuclear factor-kappaB (NF- B) pathways [16].  
The JAK family of cytoplasmic protein tyrosine kinases comprises JAK1, JAK2, JAK3, 
and tyrosine kinase 2. JAKs bind to type 1 and type 2 cytokine receptors and transmit 
extracellular cytokine signals to activate STAT proteins (STAT1/2/3/4/5A/5B/6), which 
translocate to the nucleus and modulate transcription of effector genes [17]. JAK-STAT 
signaling is initiated by binding of cytokines to their respective receptors on the cell surface 
and utilized by >50 cytokines [18]. Therefore, JAKs represent excellent targets for therapeutic 
interventions for various cytokine-mediated disorders. Baricitinib, a selective inhibitor of 
JAK1 and JAK2 [19], has been approved for the treatment of moderate-to-severe active 
rheumatoid arthritis. Although this drug is administered orally due to its small molecular 
weight, it has comparable efficacy with biological disease-modifying anti-rheumatic drugs, 
which require intravenous or subcutaneous injection [20].  
In this study, we tested the hypothesis that baricitinib can suppress CXCL10 
overexpression in LSGs of pSS patients. Additionally, we determined the in vitro effect of 
baricitinib on IFN- -induced CXCL10 expression and chemotaxis using a human salivary 
gland cell clone. 
 





Twelve female patients with pSS and three healthy female subjects were enrolled in this study. 
All individual participants enrolled in the study were treated at Tokushima University 
Hospital between 2011 and 2017. All pSS patients satisfied the revised Japanese Ministry of 
Health criteria for the diagnosis of SS [21] and the American College of Rheumatology 
classification criteria for SS [22]. Based on the biopsy scoring system described by Tarpley 
et al. [23], we categorized LSG biopsy samples from pSS patients into four groups according 
to the grade of infiltration: Grade 1, Tarpley score 1 (1–2 lymphocytic aggregates/lobule), 
Grade 2, Tarpley score 2 (2–3 lymphocytic aggregates/lobule); Grade 3, Tarpley score 3 
(diffuse infiltration through acini associated with partial destruction of acinar tissue); and 
Grade 4 Tarpley score 4 (diffuse infiltration associated with complete loss of tissue 
architecture). Healthy controls were subjects who had experienced subjective symptoms of 
oral dryness but met none of the objective criteria for SS diagnosis.  
All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the Institutional Review Board of Tokushima 
University Hospital (#2802) and with the 1964 Helsinki declaration and its later amendments. 
Written informed consent was obtained from all individual participants included in the study, 
and this process was documented by the Institutional Review Board of Tokushima University 
Hospital. The informed consent procedure was approved by the Ethics Committee of 






Formalin-fixed paraffin-embedded LSG sections from pSS patients and healthy subjects were 
deparaffinized in xylene and rehydrated with graded ethanol (100%, 95%, 70%, and 50%). 
Antigen retrieval was performed by microwave treatment using a citrate-based antigen 
unmasking solution (Vector Laboratories, Burlingame, CA, USA) according to manufacturer 
instructions. Endogenous biotin was blocked using Blocking One reagent (Nacalai Tesque, 
Kyoto, Japan) according to manufacturer instructions. Sections were then incubated overnight 
at 4 °C with rabbit polyclonal anti-human JAK1 (1:100; Cell Signaling Technology, Beverly, 
MA, USA) and rabbit polyclonal anti-human JAK2 (1:50; Cell Signaling Technology) 
primary antibodies. After three washes with phosphate-buffered saline, the sections were 
incubated for 30 min at 20 °C with horseradish peroxidase (HRP)-conjugated second antibody 
(Nichirei Biosciences Inc., Tokyo, Japan). HRP was reacted with the 3,3 -diaminobenzidine 
substrate using the Histofine Simple Stain MAX PO kit (Nichirei Biosciences Inc.), and the 
sections were observed using a light microscope equipped with a digital camera (BZ-X700; 
Keyence, Tokyo, Japan). 
 
Cell culture 
The detailed characteristics of the immortalized normal human salivary gland ductal 




keratinocyte serum-free medium (Gibco, Gaithersburg, MD, USA) in an incubator at 37 °C 
with a humidified atmosphere containing 5% CO2. Jurkat human leukemic T cells (Riken Cell 
Bank, Ibaraki, Japan) were maintained in RPMI-1640 medium (Gibco) supplemented with 
10% fetal bovine serum (Gibco) in a 5% CO2-humidified incubator at 37 °C. 
 
Reagents 
Baricitinib was purchased from MedChemExpress (Monmouth Junction, NJ, USA), and 
recombinant human IFN-  was purchased from R&D Systems (Minneapolis, MN, USA).  
 
Cell viability assay 
NS-SV-DC cells (1 × 104 cells/well) were seeded in 96-well plates (Falcon, Oxnard, CA, 
USA) in serum-free keratinocyte medium. After 24 h, the cells were treated with baricitinib 
(10, 100, 1000, 2500, or 5000 nM), and following an appropriate incubation period, an 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Roche, Basel, 
Switzerland) was added to each well for an additional 4-h incubation. The cells were then 
dissolved in solubilization solution (Roche) and analyzed at 570 nm using a Multiskan JX 
microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). 
 




NS-SV-DC cells were treated for 6, 12, or 24 h with 10 ng/mL IFN-  in the presence or 
absence of baricitinib (10, 100, or 1000 nM), followed by isolation of total RNA using TRIzol 
reagent (Life Technologies, Carlsbad, CA, USA) according to manufacturer instructions. 
Total RNA was then converted into cDNA using the PrimeScript RT reagent kit (TaKaRa, 
Kusatsu, Japan) according to manufacturer instructions. mRNA levels of CXCL10 and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were analyzed using corresponding 
Assays-on-Demand Gene Expression products (Applied Biosystems, Tokyo, Japan) and 
TaqMan Universal PCR master mix (Applied Biosystems) with an ABI Prism 7000 sequence 
detection system (Applied Biosystems) according to manufacturer instructions. The thermal 
cycler conditions were 95 °C for 10 min, followed by 40 cycles of 95 °C for 5 s and 60 °C for 
30 s. Gene-expression data were analyzed using the 2  method in Sequence Detection 
System software (v.1.0; Applied Biosystems). The relative quantification (RQ) of the fold 
change in gene expression was calculated using the formula RQ = 2  and normalized 
using GAPDH as an internal reference. The relative mRNA levels were expressed as fold 
increases relative to GAPDH level. 
 
Enzyme-linked immunosorbent assay (ELISA) 
NS-SV-DC cells were incubated for 6, 12, or 24 h with 10 ng/mL IFN- in the presence or 
absence of baricitinib (10, 100, or 1000 nM). The supernatants were collected, and secreted 




to manufacturer instructions. Absorbance at 450 nm was measured using a Multiskan JX 
microplate reader (Thermo Fisher Scientific), and CXCL10 levels were determined using a 
standard curve. 
 
Protein isolation and western blot analysis 
NS-SV-DC cells were treated for 5, 10, 30, or 60 min with 10 ng/mL IFN-  in the presence or 
absence of 100 nM baricitinib, followed by preparation of cytoplasmic lysates using NE-PER 
nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific) according to 
manufacturer instructions. Cytoplasmic lysate proteins (10 g) were separated by 
electrophoresis using 10% sodium dodecyl sulfate polyacrylamide gels (Bio-Rad, Hercules, 
CA, USA), followed by transfer onto nitrocellulose membranes (Bio-Rad). The membranes 
were blocked with 3% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 
20 (TBS-T) and incubated for 1 h at 20 °C with anti-STAT1, anti-phospho-STAT1, 
anti-STAT3, anti-phospho-STAT3, and anti- -actin primary antibodies (all from Cell 
Signaling Technology) diluted 1:1000 in Can Get Signal Solution 1 (TOYOBO, Osaka, Japan). 
After several washes with TBS-T, the membranes were incubated for 1 h at 20 °C with 
appropriate secondary antibodies (Cell Signaling Technology) diluted 1:1000 in Can Get 
Signal Solution 2 (TOYOBO). The immune complexes were visualized using an enhanced 
chemiluminescence western blotting detection reagent (GE Healthcare, Little Chalfont, UK). 




determine the relative intensity of the immune complexes and using -actin as an internal 
reference. 
 
Cell migration assay 
We analyzed Jurkat T cell directional migration, which was induced by conditioned medium 
(CM) derived from IFN- -treated NS-SV-DC cells, using a CytoSelect 96-well cell migration 
assay (5 μm; Fluorometric Format; Cell Biolabs, San Diego, CA, USA) according to 
manufacturer instructions. Briefly, NS-SV-DC cells were treated with 10 ng/mL IFN- in the 
presence or absence of 100 nM baricitinib for 24 h, followed by transfer of 150 μL of CM 
into the bottom wells (feeder tray). Serum-free medium containing 5  105 Jurkat T cells (100 
μL) was then placed in the migration chamber, and the chemotaxis plate was cultured at 37 °C 
for 24 h. After incubation, the cells that had migrated to the lower chambers were incubated 
for 20 min with 50 μL of lysis buffer/dye Solution (Cell Biolabs). Fluorescence was read at 
480/520 nm, and values were expressed as relative fluorescence units (RFUs). The 






All statistical analyses were performed using SPSS (v.15.0; SPSS Inc., Chicago, IL USA). 
Data were analyzed using the non-parametric two-tailed Mann–Whitney U test, and statistical 
significance was defined as a p < 0.05. 
 
RESULTS 
Expression of JAK1 and JAK2 in LSG sections from pSS patients and healthy controls 
To assess the efficacy of a highly selective JAK1 and JAK2 inhibitor (baricitinib) as a 
therapeutic agent for pSS patients, we used immunohistochemical staining to examine 
expression levels and localization of JAK1 and JAK2 in LSGs from SS patients and healthy 
controls. Representative data from both groups are shown in Fig. 1. In both healthy controls 
and pSS patients, JAK1 showed particularly intense staining in ductal cells and to a lesser 
extent in acinar cells. By contrast, although JAK2 showed intense staining in acinar cells from 
healthy controls, it was also observed in ductal cells. In Grade 1 pSS patients showing slight 
lymphocytic infiltration, JAK2 expression appeared similar to that in healthy controls, 
whereas Grades 2 through 4 pSS patients with moderate-to-severe lymphocytic infiltration 
showed diminished JAK2 expression in acinar cells. Additionally, we observed enhanced 
JAK2 levels at a lesion displaying immune-cell infiltration around the ductal structure. These 
results indicated that JAK1 and JAK2 were present in both healthy controls and pSS patients.  
 




We then examined the effects of baricitinib on NS-SV-DC cell viability by MTT assay. 
Following treatment of NS-SV-DC cells with various concentrations of baricitinib for up to 3 
days, we observed no effect on NS-SV-DC viability and no significant difference in viability 
at doses ranging from 10 nM to 5000 nM (Fig. 2).  
 
Effects of baricitinib on CXCL10 expression and protein secretion in IFN- -stimulated 
NS-SV-DC cells 
We previously determined whether IFN- IFN- tumor necrosis factor- and interleukin-
could regulate CXCL10 expression in human salivary gland cell lines, revealing that 
IFN- -stimulated ductal cells were mainly responsible for CXCL10 overexpression in the 
salivary glands of pSS patients [16]. In the present study, we performed RT-qPCR analyses to 
explore the potential involvement of baricitinib in regulation of IFN- -induced CXCL10 
expression. Following treatment of NS-SV-DC cells with 10 ng/mL IFN-  in the presence or 
absence of baricitinib (10, 100, or 1000 nM), we observed significant suppression of CXCL10 
mRNA levels (p < 0.05) in IFN- -stimulated NS-SV-DC cells in a dose-dependent manner 
(Fig. 3a). 
To further evaluate the effects of baricitinib, we performed an ELISA to measure secreted 
CXCL10 levels in supernatants of NS-SV-DC cells treated with IFN- in the presence or 




CXCL10 levels (p < 0.05) in a dose-dependent manner (Fig. 3b), suggesting that JAKs were 
involved in IFN- -induced CXCL10 production in salivary gland ductal cells. 
 
Effects of baricitinib on IFN- -induced STAT1 and STAT3 phosphorylation in 
NS-SV-DC cells 
IFN- or ( ) and activates JAK1 and JAK2, leading to primary 
phosphorylation of STAT1 and secondarily of STAT3, resulting in their translocation to the 
nucleus in order to bind conserved DNA elements. We previously reported that IFN-
stimulated the production of CXCL10 via the JAK/STAT pathway in salivary gland ductal 
cells [16]. To evaluate the effects of baricitinib on IFN- -induced STAT1 and STAT3 
phosphorylation in NS-SV-DC cells, we performed western blot analyses of extracts from 
NS-SV-DC cells treated with 10 ng/mL of IFN-  in the presence or absence of baricitinib 
(100 nM). The results demonstrated that baricitinib suppressed IFN- -induced 
phosphorylation of STAT1 and STAT3 in NS-SV-DC cells (Fig. 4a), with quantitative data 
revealing stronger suppression of STAT1 phosphorylation by baricitinib relative to STAT3 
phosphorylation (Fig. 4b). 
 
Effects of baricitinib on the chemotaxis of Jurkat T cells 
Because a previous report indicated that CXCL10 promotes accumulation of CXCR3+ T cells 




Jurkat T cells by IFN- -treated NS-SV-DC cells. Migration assays demonstrated that the 
chemotaxis of Jurkat T cells increased in the presence of IFN- -treated NS-SV-DC cells as 
compared with untreated NS-SV-DC cells. Additionally, baricitinib treatment significantly 
inhibited the observed IFN- -mediated chemotaxis of Jurkat T cells (p < 0.05) (Fig. 5). These 




This is the first study to elucidate the effect of baricitinib, a selective inhibitor of JAK1 and 
JAK2, on IFN-induced CXCL10 expression in salivary gland cell clones. Although SS is a 
chronic autoimmune disease that affects exocrine glands, such as salivary and lacrimal glands, 
it also causes systemic autoimmune lesions [1–3]. The clinical symptoms of SS include both 
extraglandular (systemic) and glandular symptoms, such as dryness and swelling [2]. 
Histologically, SS patients exhibit selective and progressive destruction of the acinar 
structures in LSGs, resulting in infiltration of various immune cells [4], with destruction of 
the acinar structures resulting in reduced salivary flow. Gene-expression profiling of LSGs 
shows that CXCL10 expression is upregulated in pSS patients [8]. CXCL10 is involved in the 
accumulation of infiltrating CXCR3+ immune cells and SS pathogenesis in the salivary glands 
of pSS patients [14, 15]. We recently reported that IFN- is responsible for CXCL10 




significantly secrete CXCL10 [16]. Furthermore, in vitro results showed that IFN- enhanced 
CXCL10 production via both the JAK/STAT and NF- B pathways [16]. These findings 
suggested that JAK inhibitors might inhibit CXCL10 production in salivary glands and 
suppress destruction of acinar cells.  
JAK1 and JAK2 are ubiquitously expressed in various tissues [25]; however, to the best 
of our knowledge, their expression in LSGs has not been investigated. In the present study, 
immunohistochemical analyses using LSG sections from control subjects showed that JAK1 
and JAK2 localization differed (i.e., JAK1 was strongly expressed in ductal cells, whereas 
JAK2 was strongly expressed in acinar cells). In the LSGs of pSS patients, the 
JAK1-expression pattern was similar to that of control subjects; however, JAK2 expression in 
acinar cells appeared to diminish along with increasing lymphocytic infiltration, possibly 
indicating that JAK2 phosphorylation increases along with infiltration grade. These findings 
suggested that JAK1 and JAK2 inhibition by baricitinib could represent a potential treatment 
for pSS. 
Clinical trials for pSS have generally failed, because the majority of enrolled patients 
showed no extraglandular manifestations at the time of enrollment but rather suffered from 
fatigue, dryness, and pain that did not significantly respond to the study medication [26]. 
Improving xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eye) are mostly 
required for patients with pSS. Therefore, we concluded that treatment of pSS is important to 




blockade of JAK-STAT signaling might inhibit both IFN- -induced CXCL10 expression and 
chemotaxis in the salivary glands of pSS patients. Therefore, we investigated the in vitro 
pharmacological profile of baricitinib, a novel selective inhibitor of JAK1 and JAK2, using a 
human salivary gland cell line in order to evaluate its therapeutic potential for treating pSS. 
In vitro experiments using immortalized human salivary gland ductal cells, RT-qPCR, 
and ELISA demonstrated that baricitinib treatment significantly suppressed IFN- -induced 
CXCL10 expression in a dose-dependent manner. Additionally, IFN-  induced rapid 
phosphorylation of both STAT1 and STAT3, whereas these activities were inhibited by 
baricitinib treatment. These results suggested that baricitinib inhibited IFN- -induced 
CXCL10 expression in NS-SV-DC cells by suppressing the activation of JAK/STAT signaling.  
Previous studies reported that CXCL10 is expressed in the salivary ductal glands of SS 
patients and accumulates in CXCR3+ immune cells in the LSGs of SS patients [14, 15]. In the 
present study, we performed migration assays to investigate whether baricitinib can inhibit 
immune-cell accumulation. We found that the migration of Jurkat T cells was stimulated in 
response to CM obtained from IFN- -treated NS-SV-DC cells. This finding is consistent with 
the histopathology of LSGs from SS patients (i.e., showing periductal infiltration of T cells). 
Notably, in the presence of baricitinib, we observed significant suppression of Jurkat T cell 
migration. This result suggests that baricitinib contributed to inhibition of T cell chemotaxis 





In conclusion, this study provides new insight into the underlying molecular mechanism 
of baricitinib by demonstrating its ability to suppress IFN- -induced CXCL10 expression via 
inhibition of JAK/STAT signaling in human salivary gland ductal cells. Furthermore, 
baricitinib inhibited the chemotaxis of Jurkat T cells by reducing CXCL10 production and 
secretion by salivary gland ductal cells. These findings suggest baricitinib as a potential 
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Fig. 1 Expression of JAK1 and JAK2 in LSG sections from pSS patients and healthy controls. 
LSG biopsy samples from 12 SS patients categorized into four groups according to the grade 
of infiltration. Healthy controls included subjects who had experienced subjective symptoms 
of oral dryness but met none of the objective criteria for SS diagnosis. Representative images 
are shown. Scale bars: 100 μm. 
 
Fig. 2 Effects of baricitinib on NS-SV-DC cell viability. NS-SV-DC cells (1 × 104 cells/well) 
were seeded into 96-well plates and after a 24-h incubation with baricitinib (10, 100, 1000, 
2500, or 5000 nM). At the indicated time intervals, cell growth was evaluated by MTT assay. 
SD. 
 
Fig. 3 Effects of baricitinib on CXCL10 expression and protein secretion in IFN- -stimulated 
NS-SV-DC cells. (a) Histogram showing relative changes in CXCL10 mRNA levels in 
NS-SV-DC cells treated for 6, 12, or 24 h with 10 ng/mL IFN-  in the presence or absence of 
baricitinib (10, 100, or 1000 nM). Untreated cells were used as a control. Fold changes in 
mRNA levels were evaluated by RT-qPCR using GAPDH mRNA as an internal reference. 
Data represent the SD of three independent experiments. *p < 0.05, two-tailed Mann–
Whitney U test. (b) Histogram showing the concentration of CXCL10 measured by ELISA in 




presence or absence of baricitinib (10, 100, or 1000 nM). Untreated cells were used as a 
control. Data represent the mean  SD of three independent experiments. *p < 0.05, 
two-tailed Mann–Whitney U test. 
 
Fig. 4 Effects of baricitinib on IFN- -induced STAT1 and STAT3 phosphorylation in 
NS-SV-DC cells. (a) Representative western blot analysis showing STAT1, phospho-STAT1 
(P-STAT1), STAT3, and phospho-STAT3 (P-STAT3) levels in NS-SV-DC cells treated for 
various time periods (5, 10, 30, or 60 min) with 10 ng/mL IFN-  in the presence or absence of 
100 nM baricitinib. -actin was used as an internal control. (b) Histogram showing relative 
protein levels normalized against that of -actin. 
 
Fig. 5 Effects of baricitinib on the chemotaxis of Jurkat T cells. NS-SV-DC cells were treated 
with 10 ng/mL IFN- in the presence or absence of baricitinib (100 nM ) for 24 h. Serum-free 
Jurkat T cells were placed in the migration chamber, and the chemotaxis plate was incubated 
at 37 °C for 24 h. Fluorescence values (480/520 nm) are expressed as RFUs. Data represent 
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